

# ISOLATED INTRAMURAL GASTRIC METASTASIS OF PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) DETECTED ON SURVEILLANCE ESOPHAGOGASTRODUODENOSCOPY (EGD) BEFORE ENDOSCOPIC ULTRASOUND (EUS) GUIDED BIOPSY Arjun Chatterjee<sup>1</sup>, Andrew Ford<sup>1</sup>, Amandeep Singh<sup>2</sup>, Prabhleen Chahal<sup>2</sup>



Departments of Internal Medicine<sup>1</sup>; Gastroenterology and Hepatology<sup>2</sup>; Pathology<sup>3</sup>; Cleveland Clinic Foundation, Cleveland OH

## Introduction

- PDAC is an aggressive malignancy that requires prompt diagnosis and treatment to provide the patient with the best chance of long-term survival.<sup>1</sup>
- Patients who have an imaging-confirmed solitary pancreatic mass generally undergo a EUS-guided fine needle biopsy (FNB) for histological confirmation of the diagnosis.<sup>2</sup>

## Aim

We describe a rare case of solitary intramural gastric metastases discovered on surveillance EGD prior to EUS-guided biopsy.

## Figure Legends

Figure 1a: EGD demonstrating 2cm submucosal, non-circumferential mass in the gastric fundus.

Figure 1b: EUS demonstrating a 2.1 cm intramural mass in the gastric fundus originating from the muscularis propria.


Figure 1c: EUS demonstrating 3.9-cm x 3.8-cm mass in the pancreatic body with invasion into the superior mesenteric vein, splenic vein, and splenoportal confluence with no noted arterial involvement

#### Case

- 63-year-old male with a past medical history of hypertension, chronic pancreatitis, and tobacco use presented with two months history of epigastric pain, and 5lbs weight loss.
- He denied jaundice, loss of appetite, pale-colored stools, or generalized itching.
- Initial CT abdomen showed a **2.7cm x2.6cm mass in the pancreas body** with associated proximal pancreatic duct dilatation and atrophy, suspicious of pancreatic neoplasm.
- Ca19-9 was 111, and CEA was 1.1. No evidence of metastasis was found on the CT chest/abdomen. EUS-guided FNB was scheduled.
- At the beginning of the procedure, a surveillance EGD was performed which showed a 2cm submucosal, non-circumferential mass in the gastric fundus (Figure 1a).
- EUS was performed next which confirmed a 2.1 cm intramural mass in the gastric fundus originating from the muscularis propria (Figure 1b), and a 3.9cm x 3.8cm mass in the pancreatic body with invasion into superior mesenteric vein, splenic vein, and splenoportal confluence with no noted arterial involvement (Figure 1c).
- EUS-guided FNB of both lesions was obtained using separate needles. Histopathology from both biopsies demonstrated invasive adenocarcinoma, histomorphologically similar and suggestive of a pancreatic primary. This changed the staging of the patient from borderline resectable to metastatic and he was referred for palliative chemotherapy.

## Discussion

- Isolated gastric metastasis of PDAC is extremely rare, and documented cases in the literature are from a prior diagnostic biopsy that created a seeding tract.<sup>3</sup>
- Our case highlights two major points:
  - 1) Though rare, isolated intramural gastric metastasis can occur and can be missed on cross-sectional imaging.
  - 2) Currently there is no consensus or guideline that mandates an EGD prior to EUS.
- In this case, this significant finding which changed the staging, treatment, and prognosis of the patient could have been missed with an oblique viewing EUS scope.
- At our center, we routinely perform EGD prior to EUS. Prospective studies are needed to confirm the utility of this practice.



### References

- 1. Vincent A, Herman J, Schulick R, Hruban RH, et al. Pancreatic cancer. Lancet. 2011;378(9791):607-620.
- 2. Harewood GC, Wiersema MJ. Endosonography-guided fine needle aspiration biopsy in the evaluation of pancreatic masses. Am J Gastroenterol. 2002;97(6):1386-1391.
- 3. Rothermel LD, Strosberg C, Centeno BA, et al. Case Report of Isolated Gastric Metastasis of Pancreatic Cancer From a Diagnostic Biopsy: Management of a Rare Oncologic Entity. Cancer Control. 2020;27(1).

Contact Information: Arjun Chatterjee, MD | Department of Internal Medicine, Cleveland Clinic Foundation | Email: chattea2@ccf.org | Phone: 216.399.9959